These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7924193)

  • 1. HIV-1 burden as a marker of disease progression and clinical response to therapy in AIDS.
    Coombs RW
    Clin Lab Med; 1994 Jun; 14(2):301-11. PubMed ID: 7924193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Recommendation of GESIDA (AIDS Study Group)/National Plan on AIDS with respect to the anti-retroviral treatment in adult patients infected with the human immunodeficiency virus in the year 2000 (I)].
    Miró JM; Antela A; Arrizabalaga J; Clotet B; Gatell JM; Guerra L; Iribarren JA; Laguna F; Moreno S; Parras F; Rubio R; Santamaría JM; Viciana P
    Enferm Infecc Microbiol Clin; 2000; 18(7):329-51. PubMed ID: 11109725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CPCRA to use viral load as marker for treatment. Community Programs for Clinical Research on AIDS.
    AIDS Alert; 1995 Aug; 10(8):105-7. PubMed ID: 11362678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current HIV clinical trial design issues.
    Lange JM
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S47-51. PubMed ID: 8595508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling the short-, middle- and long-term viral load responses for comparing estimated dynamic parameters.
    Huang Y
    Biom J; 2007 Jun; 49(3):429-40. PubMed ID: 17623347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measuring viral load in the clinical setting.
    Harrigan R
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S34-40. PubMed ID: 8595506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group.
    Ellis RJ; Hsia K; Spector SA; Nelson JA; Heaton RK; Wallace MR; Abramson I; Atkinson JH; Grant I; McCutchan JA
    Ann Neurol; 1997 Nov; 42(5):679-88. PubMed ID: 9392566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Directions in HIV/AIDS research. A Minnesota perspective.
    Henry K; Melroe H; Nelson R
    Minn Med; 1995 Nov; 78(11):26-34. PubMed ID: 8531902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The standpoint of AIDS research and therapy programs.
    Romano G; Massi D; Giordano A
    Anticancer Res; 1998; 18(4B):2763-78. PubMed ID: 9713460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV infection and AIDS: new biology, therapeutic advances, and clinical implications. Introduction.
    Miles SA
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997; 16 Suppl 1():S1-2. PubMed ID: 9389309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low dose methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone with zalcitabine in patients with acquired immunodeficiency syndrome-related lymphoma. Effect on human immunodeficiency virus and serum interleukin-6 levels over time.
    Levine AM; Tulpule A; Espina B; Boswell W; Buckley J; Rasheed S; Stain S; Parker J; Nathwani B; Gill PS
    Cancer; 1996 Aug; 78(3):517-26. PubMed ID: 8697399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection.
    Carcelain G; Tubiana R; Samri A; Calvez V; Delaugerre C; Agut H; Katlama C; Autran B
    J Virol; 2001 Jan; 75(1):234-41. PubMed ID: 11119593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintaining antiretroviral therapy reduces the risk of AIDS-defining events in patients with uncontrolled viral replication and profound immunodeficiency.
    Kousignian I; Abgrall S; Grabar S; Mahamat A; Teicher E; Rouveix E; Costagliola D;
    Clin Infect Dis; 2008 Jan; 46(2):296-304. PubMed ID: 18171266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiretroviral drug treatment for HIV/AIDS.
    Goldschmidt RH; Moy A
    Am Fam Physician; 1996 Aug; 54(2):574-80, 587-8. PubMed ID: 8701838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of tonsillar tissue HIV-1 viral burden at baseline and after 1 year of antiretroviral therapy.
    Navarrete P; Morente V; García F; Alós L; Arnedo M; Plana M; Gil C; Caballero M; Miró JM; Martínez E; Fumero E; Castro P; Blanco JL; Mallolas J; Blanch JL; Cruceta A; Mestre G; Pumarola T; Gallart T; Gatell JM
    Antivir Ther; 2003 Dec; 8(6):635-7. PubMed ID: 14760898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses.
    Markowitz M; Vesanen M; Tenner-Racz K; Cao Y; Binley JM; Talal A; Hurley A; Jin X; Chaudhry MR; Yaman M; Frankel S; Heath-Chiozzi M; Leonard JM; Moore JP; Racz P; Nixon DF; Ho DD
    J Infect Dis; 1999 Mar; 179(3):527-37. PubMed ID: 9952358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment-mediated changes in human immunodeficiency virus (HIV) type 1 RNA and CD4 cell counts as predictors of weight growth failure, cognitive decline, and survival in HIV-infected children.
    Lindsey JC; Hughes MD; McKinney RE; Cowles MK; Englund JA; Baker CJ; Burchett SK; Kline MW; Kovacs A; Moye J
    J Infect Dis; 2000 Nov; 182(5):1385-93. PubMed ID: 11010839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individualization of therapy using viral markers.
    Merigan T
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S41-6. PubMed ID: 8595507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.